Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04807894 · ClinicalTrials.gov registry record · Phase 4
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
A Phase 4 study of Vaginal Atrophy and Recurrent Urinary Tract Infection, sponsored by Maimonides Medical Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04807894 is a Phase 4 study of Vaginal Atrophy and Recurrent Urinary Tract Infection that is actively recruiting participants, run by Maimonides Medical Center. The registered enrollment target is 100 participants, below the 345-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04807894, a Phase 4 study of Vaginal Atrophy and Recurrent Urinary Tract Infection, is actively recruiting participants, sponsored by Maimonides Medical Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause. After menopause, there is a chemical changes in the vagina that may predispose to bacterial infections. The role of vaginal estrogen creams to restore vaginal atrophy and prevent urinary tract infections has been well characterized. Vaginal testosterone (VT) application use in postmenopausal breast cancer patients on aromatase inhibitors have been shown to improve vaginal pH, vaginal atrophy symptom scores, dyspareunia, and vaginal dryness. Although testosterone has been used to improve sexual function in postmenopausal women, the effects of VT on vaginal flora and recurrent UTIs are unknown. The purpose of this study is to determine whether topically applied vaginal testosterone cream is more effective than placebo in reducing the incidence of urinary tract infections in postmenopausal women with recurrent urinary tract infections and to ascertain the effects of topical estrogen on the vaginal pH and flora.
Conditions Studied
Interventions
- DRUG Vaginal Cream with Applicator
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04807894
The ClinicalTrials.gov registry entry for NCT04807894 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 345-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (71% lower). The listed sponsor is Maimonides Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Vaginal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which Vaginal Cream with Applicator is the first listed.
NCT04807894 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04807894 about?
NCT04807894 is a clinical study titled "Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo". Women over the age of 60 years have an estimated 10 to 15 % risk of recurrent urinary tract infections (UTI). This is believed to be due to hormonally induced changes in the vaginal flora associated with menopause. After menopause, there is a chemical changes in the vagina that may predispose to bac...
What is the current status of trial NCT04807894?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2020-11-01. Estimated completion is 2026-12-31.
What conditions does trial NCT04807894 study?
This clinical trial studies the following conditions: Vaginal Atrophy, Recurrent Urinary Tract Infection, Postmenopausal Disorder.
What interventions are being tested in trial NCT04807894?
The interventions under investigation include: Vaginal Cream with Applicator (DRUG).
Who is sponsoring clinical trial NCT04807894?
This trial is sponsored by Maimonides Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04807894 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaginal Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Postpartum Vaginal Estrogen for Breastfeeding Patients
RECRUITING · Phase 4
-
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
RECRUITING · Phase 4
-
Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy
COMPLETED · Phase 4
-
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
RECRUITING · NA
-
PRP Injections for Genitourinary Syndrome of Menopause
ACTIVE NOT RECRUITING · NA
-
Topical DHEA Against Vaginal Atrophy
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.